七、参考文献

［1］Williams ED，Sandler M.The classification of carcinoid tumours［J］.Lancet（London，England），1963，1（7275）：238-239.

［2］Ramage JK，Ahmed A， Ardill J，et al.Guidelines for the management of gastroenteropancreatic neuroendocrine（including carcinoid）tumours （NETs）［J］.Gut，2012，61（1）：6-32.

［3］Vinik AI，Chaya C.Clinical Presentation and Diagnosis of Neuroendocrine Tumors［J］.Hematology/Oncology Clinics of North America，2016，30（1）：21-48.

［4］Okuma HS，Iwasa S，Shoji H，et al.Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus［J］.Anticancer Res，2014，34（9）：5037-5041.

［5］Chen WW，Wang F，Chen S，et al.Detailed analysis of prognostic factors in primary esophageal small cell carcinoma［J］.Ann Thorac Surg，2014，97（6）：1975-1981.(https://www.daowen.com)

［6］Wong AT，Shao M，Rineer J，et al.Treatment and survival outcomes of small cell carcinoma of the esophagus：an analysis of the National Cancer Data Base［J］.Dis Esophagus，2017，30（2）：1-5.

［7］Zhang W，Wang P，Pang Q.Immune checkpoint inhibitors for esophageal squamous cell carcinoma：a narrative review［J］.Ann Transl Med，2020，8（18）：1193.

［8］Kato K，Shah MA，Enzinger P，et al.KEYNOTE-590：PhaseⅢstudy of firstline chemotherapy with or without pembrolizumab for advanced esophageal cancer［J］.Future Oncol，2019，15（10）：1057-1066.

［9］Zhao Q，Chen YX，Wu QN，et al.Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment［J］.Clin Transl Immunology，2020，9（10）：e1173.

（杨 峥）